TCON Stock - TRACON Pharmaceuticals, Inc.
Unlock GoAI Insights for TCON
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $12.04M | N/A | $346,000 | N/A | N/A |
| Gross Profit | $12.03M | $-16,000 | $332,000 | $-12,000 | $-22,000 |
| Gross Margin | 99.9% | N/A | 96.0% | N/A | N/A |
| Operating Income | $-6,898,000 | $-27,894,000 | $-28,347,000 | $-16,223,000 | $-22,296,000 |
| Net Income | $-3,588,000 | $-29,312,000 | $-28,726,000 | $-17,326,000 | $-22,658,000 |
| Net Margin | -29.8% | N/A | -8302.3% | N/A | N/A |
| EPS | $-2.20 | $-28.02 | $-33.30 | $-38.63 | $-149.35 |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
TCONEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 11, 2025 | — | — | — | — |
Q2 2025 | May 12, 2025 | — | — | — | — |
Q1 2025 | Mar 7, 2025 | — | — | — | — |
Q4 2024 | Nov 19, 2024 | — | — | — | — |
Q3 2024 | Aug 13, 2024 | $-1.05 | $-0.94 | +10.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.20 | $-1.33 | -10.8% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-0.60 | $0.20 | +133.3% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.06 | $5.80 | +9766.7% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-7.20 | $-1.20 | +83.3% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-5.80 | $-7.20 | -24.1% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-5.60 | $-6.20 | -10.7% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-6.00 | $-6.00 | 0.0% | = MET |
Q3 2022 | Aug 10, 2022 | $-5.80 | $-6.20 | -6.9% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-8.20 | $-9.60 | -17.1% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-8.00 | $-8.00 | 0.0% | = MET |
Q4 2021 | Nov 3, 2021 | $-6.40 | $-7.60 | -18.7% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-6.80 | $-11.60 | -70.6% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-6.40 | $-6.60 | -3.1% | ✗ MISS |
Q1 2021 | Feb 25, 2021 | $-6.80 | $-6.20 | +8.8% | ✓ BEAT |
Q4 2020 | Nov 10, 2020 | $-12.20 | $-7.60 | +37.7% | ✓ BEAT |
Latest News
Frequently Asked Questions about TCON
What is TCON's current stock price?
What is the analyst price target for TCON?
What sector is TRACON Pharmaceuticals, Inc. in?
What is TCON's market cap?
Does TCON pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TCON for comparison